Rosenthal M, Bahous I, Ambrosini G
Department of Rheumatology, Bethesda Hospital, Basel, Switzerland.
J Rheumatol. 1991 Dec;18(12):1790-3.
OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the management of rheumatoid arthritis (RA). For this report, longterm information was collected from 32 patients (27 women, 5 men) with RA who had been treated for periods ranging from one to over 8 years with OM-8980 daily (median 5 years). Statistically significant reductions were observed in duration of morning stiffness, articular index, pain and erythrocyte sedimentation rate (ESR). An improvement or strong improvement in overall condition was noted in 23 patients. Adverse events were reported in only 3 patients and were minimal in nature. Our study demonstrates that OM-8980 is an effective longterm slow acting antirheumatic drug which has minimal adverse effects and should be considered to have a role to play in the management of RA.
OM - 8980是一种免疫调节药物，在双盲安慰剂对照试验中已证明其对类风湿性关节炎（RA）的治疗有效。在本报告中，收集了32例RA患者（27名女性，5名男性）的长期信息，这些患者每日服用OM - 8980进行治疗，治疗时间为1年至8年以上（中位数为5年）。观察到晨僵持续时间、关节指数、疼痛和红细胞沉降率（ESR）有统计学意义的降低。23例患者整体状况有改善或明显改善。仅3例患者报告了不良事件，且性质轻微。我们的研究表明，OM - 8980是一种有效的长效抗风湿药物，副作用极小，应被视为在RA治疗中发挥作用。
